The molecule has a unique activity profile for its ability of inhibiting both PIM kinase, important for cell cycle regulation, cell survival and tumorigenesis, and FLT3, a kinase involved in the onset and progression of acute myeloid leukemia (AML).

None of the molecules currently in clinical development has this dual activity.
MEN1703 started the Phase I/II clinical trial in patients with relapsed /refractory AML in March 2017.
Preclinical evidence supports clinical development not only in hematological tumors but also in solid tumors.
Technology Transfer of the manufacturing process from Selvita to Menarini is ongoing as well as preclinical studies aimed to support the design of additional clinical trials in AML and the selection of further indications in solid tumors and hematological malignancies.

• Press Release 28/03/2017
• Press Release 06/08/2018
• Press Release 23/05/2019
• Press Release 10/06/2019
• ASCO Annual Meeting 2019, May 31-June 4, Chicago
  CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia
• The PAGE 2019, 11-19 June, Stockhalm
  Development of a Translational Pharmacokinetic-Biomarker-Efficacy Model in Mouse as a Tool for the Human Therapeutic Dose Estimation
• 24th Congress of EHA, June 13-16, 2019 Amsterdam
  “CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia”